<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>DESFERAL- deferoxamine mesylate injection, powder, lyophilized, for solution </strong><br>Novartis Pharmaceuticals Corporation<br></p></div>
<h1>Desferal</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Desferal</span><span class="Bold"><span class="Sup">®</span></span></p>
<p><span class="Bold">deferoxamine mesylate for injection USP</span></p>
<p><span class="Bold">Vials</span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">Prescribing Information</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1><span class="Bold">DESCRIPTION</span></h1>
<p class="First">Desferal, deferoxamine mesylate USP, is an iron-chelating agent, available in vials for intramuscular, subcutaneous, and intravenous administration. Desferal is supplied as vials containing 500 mg and 2 g of deferoxamine mesylate USP in sterile, lyophilized form. Deferoxamine mesylate is <span class="Italics">N</span>-[5-[3-[(5-aminopentyl)hydroxycarbamoyl]propionamido]pentyl]-3-[[5-(<span class="Italics">N</span>-hydroxyacetamido)pentyl]carbamoyl]propionohydroxamic acid monomethanesul-fonate (salt), and its structural formula is</p>
<p><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a7174843-5965-49fc-b842-f7eff7b48bbc&amp;name=desferal-02.jpg"></p>
<p>Deferoxamine mesylate USP is a white to off-white powder. It is freely soluble in water and slightly soluble in methanol. Its molecular weight is 656.79.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1><span class="Bold">CLINICAL PHARMACOLOGY</span></h1>
<p class="First">Desferal chelates iron by forming a stable complex that prevents the iron from entering into further chemical reactions. It readily chelates iron from ferritin and hemosiderin but not readily from transferrin; it does not combine with the iron from cytochromes and hemoglobin. Desferal does not cause any demonstrable increase in the excretion of electrolytes or trace metals. Theoretically, 100 parts by weight of Desferal is capable of binding approximately 8.5 parts by weight of ferric iron.</p>
<p>Desferal is metabolized principally by plasma enzymes, but the pathways have not yet been defined. The chelate is readily soluble in water and passes easily through the kidney, giving the urine a characteristic reddish color. Some is also excreted in the feces via the bile.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1><span class="Bold">INDICATIONS AND USAGE</span></h1>
<p class="First">Desferal is indicated for the treatment of acute iron <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span> and of <span class="product-label-link" type="condition" conceptid="4246084" conceptname="Iron overload">chronic iron overload</span> due to transfusion-dependent <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemias</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.1"></a><p></p>
<h2><span class="Bold">Acute Iron <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">Intoxication</span></span></h2>
<p class="First">Desferal is an adjunct to, and not a substitute for, standard measures used in treating acute iron <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>, which may include the following: induction of <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> with syrup of ipecac; gastric lavage; suction and maintenance of a clear airway; control of <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> with intravenous fluids, blood, oxygen, and vasopressors; and correction of <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.2"></a><p></p>
<h2><span class="Bold"><span class="product-label-link" type="condition" conceptid="4246084" conceptname="Iron overload">Chronic Iron Overload</span></span></h2>
<p class="First">Desferal can promote iron excretion in patients with secondary <span class="product-label-link" type="condition" conceptid="4246084" conceptname="Iron overload">iron overload</span> from multiple transfusions (as may occur in the treatment of some chronic <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemias</span>, including <span class="product-label-link" type="condition" conceptid="30978" conceptname="Thalassemia">thalassemia</span>). Long-term therapy with Desferal slows accumulation of hepatic iron and retards or eliminates progression of <span class="product-label-link" type="condition" conceptid="4267417" conceptname="Hepatic fibrosis">hepatic fibrosis</span>.</p>
<p>Iron mobilization with Desferal is relatively poor in patients under the age of 3 years with relatively little <span class="product-label-link" type="condition" conceptid="4246084" conceptname="Iron overload">iron overload</span>. The drug should ordinarily not be given to such patients unless significant iron mobilization (e.g., 1 mg or more of iron per day) can be demonstrated.</p>
<p>Desferal is not indicated for the treatment of primary <span class="product-label-link" type="condition" conceptid="4163735" conceptname="Hemochromatosis">hemochromatosis</span>, since phlebotomy is the method of choice for removing excess iron in this disorder.</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1><span class="Bold">CONTRAINDICATIONS</span></h1>
<p class="First">Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the active substance.  </p>
<p>Desferal is contraindicated in patients with severe <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> or <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span>, since the drug and the iron chelate are excreted primarily by the kidney. (See WARNINGS).</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-6"></a><p></p>
<h1><span class="Bold">WARNINGS</span></h1>
<p class="First">Ocular and auditory disturbances have been reported when Desferal was administered over <span class="product-label-link" type="condition" conceptid="4088438" conceptname="Prolonged periods">prolonged periods</span> of time, at high doses, or in patients with low ferritin levels. The ocular disturbances observed have been <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurring of vision</span>; <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataracts</span> after prolonged administration in <span class="product-label-link" type="condition" conceptid="4246084" conceptname="Iron overload">chronic iron overload</span>; decreased visual acuity including visual loss, visual defects, <span class="product-label-link" type="condition" conceptid="377286" conceptname="Visual field defect">scotoma</span>; impaired peripheral, color, and night vision; <span class="product-label-link" type="condition" conceptid="374954" conceptname="Optic neuritis">optic neuritis</span>, <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataracts</span>, corneal opacities, and retinal pigmentary abnormalities. The auditory abnormalities reported have been <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span> and <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span> including high frequency <span class="product-label-link" type="condition" conceptid="374366" conceptname="Sensorineural hearing loss">sensorineural hearing loss</span>. In most cases, both ocular and auditory disturbances were reversible upon immediate cessation of treatment (see PRECAUTIONS/Information for Patients and ADVERSE REACTIONS/Special Senses).</p>
<p>Visual acuity tests, slit-lamp examinations, funduscopy and audiometry are recommended periodically in patients treated for <span class="product-label-link" type="condition" conceptid="4088438" conceptname="Prolonged periods">prolonged periods</span> of time. Toxicity is more likely to be reversed if symptoms or test abnormalities are detected early.</p>
<p>Increases in serum creatinine (possibly dose-related), <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> and <span class="product-label-link" type="condition" conceptid="4318544" conceptname="Renal tubular disorder">renal tubular disorders</span>, associated with the administration of deferoxamine, have been reported in postmarketing experience (see ADVERSE REACTIONS). Monitor patients for changes in renal function.</p>
<p>High doses of Desferal and concomitant low ferritin levels have also been associated with <span class="product-label-link" type="condition" conceptid="4245750" conceptname="Growth retardation">growth retardation</span>. After reduction of Desferal dose, growth velocity may partially resume to pretreatment rates (see PRECAUTIONS/Pediatric Use).</p>
<p><span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">Adult respiratory distress syndrome</span>, also reported in children, has been described following treatment with excessively high intravenous doses of Desferal in patients with acute iron <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span> or <span class="product-label-link" type="condition" conceptid="30978" conceptname="Thalassemia">thalassemia</span>.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-7"></a><p></p>
<h1><span class="Bold">PRECAUTIONS</span></h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-7.1"></a><p></p>
<h2><span class="Bold">General</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing</span> of the skin, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> have occurred in a few patients when Desferal was administered by rapid intravenous injection. THEREFORE, DESFERAL SHOULD BE GIVEN INTRAMUSCULARLY OR BY SLOW SUBCUTANEOUS OR INTRAVENOUS INFUSION.</p>
<p><span class="product-label-link" type="condition" conceptid="4246084" conceptname="Iron overload">Iron overload</span> increases susceptibility of patients to <span class="Italics">Yersinia enterocolitica</span><span class="Italics"> </span>and<span class="Italics"> Yersinia pseudotuberculosis</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. In some rare cases, treatment with Desferal has enhanced this susceptibility, resulting in generalized <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> by providing these bacteria with a siderophore otherwise missing. In such cases, Desferal treatment should be discontinued until the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> is resolved.</p>
<p>In patients receiving Desferal, rare cases of <span class="product-label-link" type="condition" conceptid="432830" conceptname="Zygomycosis">mucormycosis</span>, some with a fatal outcome, have been reported. If any of the suspected signs or symptoms occur, Desferal should be discontinued, mycological tests carried out and appropriate treatment instituted immediately. </p>
<p>In patients with severe <span class="product-label-link" type="condition" conceptid="4246084" conceptname="Iron overload">chronic iron overload</span>, impairment of cardiac function has been reported following concomitant treatment with Desferal and high doses of vitamin C (more than 500 mg daily in adults). The cardiac dysfunction was reversible when vitamin C was discontinued. The following precautions should be taken when vitamin C and Desferal are to be used concomitantly:</p>
<ul>
<li>Vitamin C supplements should not be given to patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>.<br>
</li>
<li>Start supplemental vitamin C only after an initial month of regular treatment with Desferal.<br>
</li>
<li>Give vitamin C only if the patient is receiving Desferal regularly, ideally soon after setting up the infusion pump.<br>
</li>
<li>Do not exceed a daily vitamin C dose of 200 mg in adults, given in divided doses.<br>
</li>
<li>Clinical monitoring of cardiac function is advisable during such combined therapy.</li>
</ul>
<p>In patients with aluminum-related <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span> and receiving dialysis, Desferal may cause neurological dysfunction (<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>), possibly due to an acute increase in circulating aluminum (see ADVERSE REACTIONS). Desferal may precipitate the onset of dialysis <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>. Treatment with Desferal in the presence of aluminum overload may result in decreased serum calcium and aggravation of <span class="product-label-link" type="condition" conceptid="133729" conceptname="Hyperparathyroidism">hyperparathyroidism</span>.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7.2"></a><p></p>
<h2><span class="Bold">Drug Interactions</span></h2>
<p class="First"><span class="Bold Italics">Vitamin C:</span> Patients with <span class="product-label-link" type="condition" conceptid="4246084" conceptname="Iron overload">iron overload</span> usually become vitamin C deficient, probably because iron oxidizes the vitamin. As an adjuvant to iron chelation therapy, vitamin C in doses up to 200 mg for adults may be given in divided doses, starting after an initial month of regular treatment with Desferal (see PRECAUTIONS). Vitamin C increases availability of iron for chelation. In general, 50 mg daily suffices for children under 10 years old and 100 mg daily for older children. Larger doses of vitamin C fail to produce any additional increase in excretion of iron complex.</p>
<p><span class="Bold Italics">Prochlorperazine</span><span class="Bold Italics">:</span><span class="Bold Italics"> </span>Concurrent treatment with Desferal and prochlorperazine, a phenothiazine derivative, may lead to temporary impairment of consciousness.</p>
<p><span class="Bold Italics">Gallium-67:</span> Imaging results may be distorted because of the rapid urinary excretion of Desferal-bound gallium-67. Discontinuation of Desferal 48 hours prior to scintigraphy is advisable.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-7.3"></a><p></p>
<h2><span class="Bold">Information for Patients</span></h2>
<p class="First">Patients experiencing <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> or other nervous system disturbances, or impairment of vision or hearing, should refrain from driving or operating potentially hazardous machines (see ADVERSE REACTIONS).</p>
<p>Patients should be informed that occasionally their urine may show a reddish discoloration.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-7.4"></a><p></p>
<h2><span class="Bold">Carcinogenesis, Mutagenesis, Impairment of Fertility</span></h2>
<p class="First">Long-term carcinogenicity studies in animals have not been performed with Desferal.</p>
<p>Cytotoxicity may occur, since Desferal has been shown to inhibit DNA synthesis in vitro.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-7.5"></a><p></p>
<h2><span class="Bold">Pregnancy Category C</span></h2>
<p class="First">Delayed ossification in mice and skeletal anomalies in rabbits were observed after Desferal was administered in daily doses up to 4.5 times the maximum daily human dose. No adverse effects were observed in similar studies in rats.</p>
<p>There are no adequate and well-controlled studies in pregnant women. Desferal should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7.6"></a><p></p>
<h2><span class="Bold">Nursing Mothers</span></h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Desferal is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-7.7"></a><p></p>
<h2><span class="Bold">Pediatric Use</span></h2>
<p class="First">Pediatric patients receiving Desferal should be monitored for body weight and growth every 3 months.</p>
<p>Safety and effectiveness in pediatric patients under the age of 3 years have not been established (see INDICATIONS AND USAGE, WARNINGS, PRECAUTIONS/Drug Interactions/Vitamin C, and ADVERSE REACTIONS).</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-7.8"></a><p></p>
<h2><span class="Bold">Geriatric Use</span></h2>
<p class="First">Clinical Studies of Desferal did not include sufficient numbers of subjects aged 65 years and over to determine whether they respond differently from the younger subjects. Postmarketing reports suggest a possible trend for an increased risk of <span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">eye disorders</span> in the geriatric population, specifically the occurrence of <span class="product-label-link" type="condition" conceptid="372633" conceptname="Deutan defect">color blindness</span>, <span class="product-label-link" type="condition" conceptid="4208223" conceptname="Disorder of macula of retina">maculopathy</span>, and <span class="product-label-link" type="condition" conceptid="377286" conceptname="Visual field defect">scotoma</span>. However, it is unclear if these <span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">eye disorders</span> were dose related. Although the number of reports was very small, certain elderly patients may be predisposed to <span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">eye disorders</span> when taking Desferal. Postmarketing reports also suggest that there may be an increased risk of <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">deafness</span> and <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span> in the geriatric population. (<span class="Italics">see ADVERSE REACTIONS</span>). In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.9"></a><p></p>
<h2><span class="Bold"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></h2>
<p class="First">No studies have been performed in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1><span class="Bold">ADVERSE REACTIONS</span></h1>
<p class="First">The following adverse reactions have been observed, but there are not enough data to support an estimate of their frequency.</p>
<p><span class="Bold Italics">At the Injection Site:</span><span class="Bold Italics"> </span>Localized irritation, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, burning, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, <span class="product-label-link" type="condition" conceptid="4165876" conceptname="Induration">induration</span>, infiltration, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, wheal formation, <span class="product-label-link" type="condition" conceptid="4337954" conceptname="Eschar">eschar</span>, crust, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">vesicles</span>, local <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>. <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">Injection site reactions</span> may be associated with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">systemic allergic reactions</span> (see Body as a Whole, below).</p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span> and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Systemic Allergic Reactions</span>:</span><span class="Bold Italics"> </span>Generalized <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span> with or without <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>. </p>
<p><span class="Bold Italics">Body as a Whole:</span> Local <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">injection site reactions</span> may be accompanied by systemic reactions like <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, or <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> with <span class="Italics">Yersinia</span> and <span class="Italics"><span class="product-label-link" type="condition" conceptid="432830" conceptname="Zygomycosis">Mucormycosis</span></span> have been reported in association with Desferal use (see PRECAUTIONS).</p>
<p><span class="Bold Italics">Cardiovascular:</span><span class="Bold Italics"> </span><span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>.</p>
<p><span class="Bold Italics">Digestive:</span><span class="Bold"> </span><span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">Abdominal discomfort</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
<p><span class="Bold Italics">Hematologic:</span> <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">Blood dyscrasia</span> (<span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leucopenia</span>).</p>
<p><span class="Bold Italics">Hepatic:</span> Increased transaminases, hepatic dysfunction.</p>
<p><span class="Bold Italics">Musculoskeletal:</span><span class="Bold"> </span><span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Muscle spasms</span>. <span class="product-label-link" type="condition" conceptid="4245750" conceptname="Growth retardation">Growth retardation</span> and bone changes (e.g., <span class="product-label-link" type="condition" conceptid="4101118" conceptname="Pyle metaphyseal dysplasia">metaphyseal dysplasia</span>) are common in chelated patients given doses above 60 mg/kg, especially those who begin iron chelation in the first three years of life. If doses are kept to 40 mg/kg or below, the risk may be reduced (see WARNINGS, PRECAUTIONS/Pediatric Use).</p>
<p><span class="Bold Italics">Nervous </span><span class="Bold Italics">S</span><span class="Bold Italics">ystem:</span><span class="Bold Italics"> </span>Neurological disturbances including <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, peripheral sensory, motor, or mixed <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>; exacerbation or precipitation of aluminum-related dialysis <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span> (see PRECAUTIONS/Information for Patients).</p>
<p><span class="Bold Italics">Special Senses:</span> High-frequency <span class="product-label-link" type="condition" conceptid="374366" conceptname="Sensorineural hearing loss">sensorineural hearing loss</span> and/or <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span> are uncommon if dosage guidelines are not exceeded and if dose is reduced when ferritin levels decline. <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">Visual disturbances</span> are rare if dosage guidelines are not exceeded. These may include decreased acuity, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span>, <span class="product-label-link" type="condition" conceptid="4092111" conceptname="Chromatopsia">dyschromatopsia</span>, <span class="product-label-link" type="condition" conceptid="374037" conceptname="Night blindness">night blindness</span>, <span class="product-label-link" type="condition" conceptid="377286" conceptname="Visual field defect">visual field defects</span>, <span class="product-label-link" type="condition" conceptid="377286" conceptname="Visual field defect">scotoma</span>, <span class="product-label-link" type="condition" conceptid="376103" conceptname="Retinopathy">retinopathy</span> (pigmentary degeneration), <span class="product-label-link" type="condition" conceptid="374954" conceptname="Optic neuritis">optic neuritis</span>, and <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataracts</span> (see WARNINGS).</p>
<p><span class="Bold Italics">Respiratory:</span> <span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">Acute respiratory distress syndrome</span> (with <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span>, and/or interstitial infiltrates) (see WARNINGS).</p>
<p><span class="Bold Italics">Skin:</span> Very rare generalized <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>.</p>
<p><span class="Bold Italics">Urogenital:</span><span class="Bold Italics"> </span><span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">Dysuria</span>, <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>, increased serum creatinine and <span class="product-label-link" type="condition" conceptid="4318544" conceptname="Renal tubular disorder">renal tubular disorders</span> (see CONTRAINDICATIONS and WARNINGS).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9"></a><p></p>
<h1><span class="Bold">Postmarketing Reports</span></h1>
<p class="First">There are postmarketing reports of deferoxamine-associated renal dysfunction, including <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>. Monitor patients for changes in renal function (e.g., increased serum creatinine).</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-10"></a><p></p>
<h1><span class="Bold">OVERDOSAGE</span></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.1"></a><p></p>
<h2><span class="Bold">Acute Toxicity</span></h2>
<p class="First">Intravenous LD<span class="Sub">50</span>s (mg/kg): mice, 287; rats, 329.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.2"></a><p></p>
<h2><span class="Bold">Signs and Symptoms</span></h2>
<p class="First">Inadvertent administration of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> or inadvertent intravenous bolus administration/rapid intravenous infusion may be associated with <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> and <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disturbances</span>; acute but transient <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span>, <span class="product-label-link" type="condition" conceptid="440424" conceptname="Aphasia">aphasia</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pallor</span>, <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span> including <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> and <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> have been reported.</p>
<p><span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">Acute respiratory distress syndrome</span> has been reported following treatment with excessively high intravenous doses of Desferal in patients with acute iron <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span> and  in patients with <span class="product-label-link" type="condition" conceptid="30978" conceptname="Thalassemia">thalassemia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.3"></a><p></p>
<h2><span class="Bold">Treatment</span></h2>
<p class="First">There is no specific antidote. Desferal should be discontinued and appropriate symptomatic measures undertaken.</p>
<p>Desferal is readily dialyzable.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-11"></a><p></p>
<h1><span class="Bold">DOSAGE AND ADMINISTRATION</span></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.1"></a><p></p>
<h2><span class="Bold">Acute Iron <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">Intoxication</span></span></h2>
<p class="First"><span class="Bold Italics">Intramuscular Administration</span></p>
<p>This route is preferred and should be used for ALL PATIENTS NOT IN <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">SHOCK</span>.</p>
<p>A dose of 1000 mg should be administered initially. This may be followed by 500 mg every 4 hours for two doses. Depending upon the clinical response, subsequent doses of 500 mg may be administered every 4-12 hours. The total amount administered should not exceed 6000 mg in 24 hours. For reconstitution instructions for intramuscular administration see Table 1.</p>
<p><span class="Bold Italics">Intravenous Administration</span></p>
<p>THIS ROUTE SHOULD BE USED ONLY FOR PATIENTS IN A STATE OF <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">CARDIOVASCULAR COLLAPSE</span> AND THEN ONLY BY SLOW INFUSION. THE RATE OF INFUSION SHOULD NOT EXCEED 15 MG/KG/HR FOR THE FIRST 1000 MG ADMINISTERED. SUBSEQUENT IV DOSING, IF NEEDED, MUST BE AT A SLOWER RATE, NOT TO EXCEED 125 MG/HR.</p>
<p>For reconstitution instructions for intravenous administration see Table 2. The reconstituted solution is added to physiologic saline, (e.g., 0.9% sodium chloride, 0.45% sodium chloride), glucose in water, or Ringer’s lactate solution.</p>
<p>An initial dose of 1000 mg should be administered at a rate NOT TO EXCEED 15 mg/kg/hr. This may be followed by 500 mg over 4 hours for two doses. Depending upon the clinical response, subsequent doses of 500 mg may be administered over 4-12 hours. The total amount administered should not exceed 6000 mg in 24 hours.</p>
<p>As soon as the clinical condition of the patient permits, intravenous administration should be discontinued and the drug should be administered intramuscularly. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2"></a><p></p>
<h2><span class="Bold"><span class="product-label-link" type="condition" conceptid="4246084" conceptname="Iron overload">Chronic Iron Overload</span></span></h2>
<p class="First"><span class="Bold Italics">Subcutaneous Administration</span></p>
<p>A daily dose of 1000-2000 mg (20-40 mg/kg/day) should be administered over 8-24 hours, utilizing a small portable pump capable of providing continuous mini-infusion. The duration of infusion must be individualized. In some patients, as much iron will be excreted after a short infusion of 8-12 hours as with the same dose given over 24 hours. For reconstitution instructions for subcutaneous administration see Table 3.</p>
<p><span class="Bold Italics">Intravenous Administration</span></p>
<p>The standard recommended method of Desferal administration is via slow subcutaneous infusion over 8 – 12 hours. In patients with intravenous access, the daily dose of Desferal can be administered intravenously.  The standard dose is 20 – 40 mg/kg/day for children and 40 – 50 mg/kg/day over 8 – 12 hours in adults for 5 – 7 days per week. In children, average doses should not exceed 40 mg/kg/day until growth has ceased. In adults, average doses should not exceed 60 mg/kg/day. The intravenous infusion rate should not exceed 15 mg/kg/hour.   For reconstitution instructions for intravenous administration see Table 2.</p>
<p>In patients who are poorly compliant, Desferal may be administered prior to or following same day blood transfusion  (for example 1 gram over 4 hours on the day of transfusion); however, the contribution of this mode of administration to iron balance is limited.  Desferal should not be administered concurrently with the blood transfusion as this can lead to errors in interpreting side effects such as <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>.</p>
<p><span class="Bold Italics">Intramuscular Administration</span></p>
<p>A daily dose of 500-1000 mg may be administered intramuscularly. The total daily dose should not exceed 1000 mg. For reconstitution instructions for intramuscular administration see Table 1.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3"></a><p></p>
<h2><span class="Bold">Reconstitution and Preparation</span></h2>
<p class="First"><span class="Bold">Table </span><span class="Bold">1</span><span class="Bold">: Preparation for Intramuscular Administration</span>
		     
	</p>
<table>
<col width="155">
<col width="155">
<col width="155">
<col width="155">
<tbody class="Headless">
<tr class="First"><td class="Toprule" colspan="4">RECONSTITUTE DESFERAL WITH STERILE WATER FOR INJECTION</td></tr>
<tr>
<td class="Toprule">Vial Size</td>
<td class="Toprule">Amount of Sterile Water for Injection Required for Reconstitution</td>
<td class="Toprule">Total Drug Content after Reconstitution</td>
<td class="Toprule">Final Concentration per mL after Reconstitution</td>
</tr>
<tr>
<td class="Toprule">500 mg</td>
<td class="Toprule">2 mL</td>
<td class="Toprule">500 mg/2.35 mL </td>
<td class="Toprule">213 mg/mL </td>
</tr>
<tr class="Last">
<td class="Toprule">2 grams</td>
<td class="Toprule">8 mL</td>
<td class="Toprule">2 grams/9.4 mL </td>
<td class="Toprule">213 mg/mL </td>
</tr>
</tbody>
</table>
<p><span class="Bold">Table </span><span class="Bold">2</span><span class="Bold">: Preparation </span><span class="Bold">for Intravenous Administrations</span></p>
<table>
<col width="155">
<col width="155">
<col width="155">
<col width="155">
<tbody class="Headless">
<tr class="First"><td class="Toprule" colspan="4">RECONSTITUTE DESFERAL WITH STERILE WATER FOR INJECTION</td></tr>
<tr>
<td class="Toprule">Vial Size</td>
<td class="Toprule">Amount of Sterile Water for Injection Required for Reconstitution</td>
<td class="Toprule">Total Drug Content after Reconstitution</td>
<td class="Toprule">Final Concentration per mL after Reconstitution</td>
</tr>
<tr>
<td class="Toprule">500 mg</td>
<td class="Toprule">5 mL</td>
<td class="Toprule">500 mg/5.3 mL </td>
<td class="Toprule">95 mg/mL</td>
</tr>
<tr class="Last">
<td class="Toprule">2 grams</td>
<td class="Toprule">20 mL</td>
<td class="Toprule">2 grams/21.1 mL</td>
<td class="Toprule">95 mg/mL </td>
</tr>
</tbody>
</table>
<p><span class="Bold">Table </span><span class="Bold">3</span><span class="Bold">: Preparation for Subcutaneous Administration</span>
		     
	</p>
<table>
<col width="155">
<col width="155">
<col width="155">
<col width="155">
<tbody class="Headless">
<tr class="First"><td class="Toprule" colspan="4">RECONSTITUTE DESFERAL WITH STERILE WATER FOR INJECTION</td></tr>
<tr>
<td class="Toprule">Vial Size</td>
<td class="Toprule">Amount of Sterile Water for Injection Required for Reconstitution</td>
<td class="Toprule">Total Drug Content after Reconstitution</td>
<td class="Toprule">Final Concentration per mL after Reconstitution</td>
</tr>
<tr>
<td class="Toprule">500 mg</td>
<td class="Toprule">5 mL</td>
<td class="Toprule">500 mg/5.3 mL </td>
<td class="Toprule">95 mg/mL</td>
</tr>
<tr class="Last">
<td class="Toprule">2 grams</td>
<td class="Toprule">20 mL</td>
<td class="Toprule">2 grams/21.1 mL</td>
<td class="Toprule">95 mg/mL </td>
</tr>
</tbody>
</table>
<p>The reconstituted Desferal solution is an isotonic, clear and colorless to slightly- yellowish solution. The drug should be completely dissolved before the solution is withdrawn. Desferal reconstituted with Sterile Water for Injection IS FOR SINGLE USE ONLY. Discard unused portion.</p>
<p>The product should be used immediately after reconstitution (commencement of treatment within 3 hours) for microbiological safety. When reconstitution is carried out under validated aseptic conditions (in a sterile laminar flow hood using aseptic technique), the product may be stored at room temperature for a maximum period of 24 hours before use. Do not refrigerate reconstituted solution. Reconstituting Desferal in solvents or under conditions other than indicated may result in precipitation. Turbid solutions should not be used.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-12"></a><p></p>
<h1><span class="Bold">HOW SUPPLIED</span></h1>
<p class="First">Vials - each containing 500 mg of sterile, lyophilized deferoxamine mesylate</p>
<p>Cartons of 4 vials……………………………………………NDC 0078-0467-91</p>
<p>Vials - each containing 2 g of sterile, lyophilized deferoxamine mesylate</p>
<p>Cartons of 4 vials……………………………………………NDC 0078-0347-51</p>
<p>Do not store above 25°C (77°F).</p>
<p><br><br>Manufactured by:</p>
<p>Novartis Pharma Stein AG</p>
<p>Stein, Switzerland</p>
<p>Distributed by:</p>
<p>Novartis Pharmaceuticals Corporation</p>
<p>East Hanover, New Jersey 07936</p>
<p>©Novartis</p>
<p>T2012-09<br>December 2011</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-13"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL</span></p>
<p><span class="Bold">Package Label – </span><span class="Bold">500 mg per vial</span></p>
<p>Rx Only
		     
	
		     
	NDC 0078-0467-91</p>
<p>Desferal® </p>
<p>deferoxamine mesylate for injection USP</p>
<p>500 mg per vial</p>
<p>Each vial contains deferoxamine mesylate USP, 500 mg in lyophilized form.</p>
<p>For subcutaneous intramuscular or intravenous administration.</p>
<p>4 vials</p>
<p><img alt="PRINCIPAL DISPLAY PANEL
Package Label – 500 mg per vial" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a7174843-5965-49fc-b842-f7eff7b48bbc&amp;name=desferal-03.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-14"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL</span></p>
<p><span class="Bold">Package Label – </span><span class="Bold">2 g per vial</span></p>
<p>Rx Only
		     
	
		     
	NDC 0078-0347-51</p>
<p>Desferal® </p>
<p>deferoxamine mesylate for injection USP</p>
<p>2 g per vial</p>
<p>4 vials</p>
<p>Each vial contains deferoxamine mesylate USP, 2 g in lyophilized form.</p>
<p>For subcutaneous intramuscular or intravenous administration.</p>
<p><img alt="PRINCIPAL DISPLAY PANEL
Package Label – 2 g per vial" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a7174843-5965-49fc-b842-f7eff7b48bbc&amp;name=desferal-04.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DESFERAL 		
					</strong><br><span class="contentTableReg">deferoxamine mesylate injection, powder, lyophilized, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0078-0467</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DEFEROXAMINE MESYLATE</strong> (DEFEROXAMINE) </td>
<td class="formItem">DEFEROXAMINE MESYLATE</td>
<td class="formItem">500 mg</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0078-0467-91</td>
<td class="formItem">4  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0078-0467-61</td>
<td class="formItem">1  in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA016267</td>
<td class="formItem">04/02/1968</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DESFERAL 		
					</strong><br><span class="contentTableReg">deferoxamine mesylate injection, powder, lyophilized, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0078-0347</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DEFEROXAMINE MESYLATE</strong> (DEFEROXAMINE) </td>
<td class="formItem">DEFEROXAMINE MESYLATE</td>
<td class="formItem">2000 mg</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0078-0347-51</td>
<td class="formItem">4  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0078-0347-61</td>
<td class="formItem">1  in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA016267</td>
<td class="formItem">04/02/1968</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Novartis Pharmaceuticals Corporation
							(002147023)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 1/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>00eb6ea3-4b93-4f9d-b879-13005d59399c</div>
<div>Set id: a7174843-5965-49fc-b842-f7eff7b48bbc</div>
<div>Version: 7</div>
<div>Effective Time: 20120101</div>
</div>
</div> <div class="DistributorName">Novartis Pharmaceuticals Corporation</div></p>
</body></html>
